Pioneering Bioconjugates With Novel Payloads & Targeting Formats

We are witnessing a surging 83% growth of novel drug conjugates, with major collaborations between Nurix & Pfizer for antibody-degrader conjugates and Bicycle & Novartis for radiopharmaceuticals. With investments booming in bispecific ADCs, peptide drug conjugates and oligonucleotide conjugates, the charge is on to make iterative and incremental improvements to ADCs to pave the way towards a new generation of more targeted, safer and efficacious novel conjugated drugs.

Encompassing the landscape of these new frontiers in targeted cancer therapy, the 4th Novel Conjugates Summit is returning as a one-stop shop to shine a spotlight on which novel approaches are currently being explored, what benefit each approach has, and provide a comprehensive assessment on how you can widen your conjugate design toolkit.

Join us next March to find the next hottest conjugate approach as we delve into emerging data and industry-leading discussions around novel bioconjugate design and development to redefine the future of targeted cancer therapies.